FY2025 EPS Estimates for VERA Decreased by Cantor Fitzgerald

Vera Therapeutics, Inc. (NASDAQ:VERA) – Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Vera Therapeutics in a research note issued on Wednesday, May 7th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($2.74) for the year, down from their previous estimate of ($2.53). Cantor Fitzgerald currently has a “Overweight” rating and a $100.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the previous year, the company earned ($0.56) earnings per share.

A number of other research firms also recently commented on VERA. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target on the stock. HC Wainwright initiated coverage on Vera Therapeutics in a research report on Monday, May 5th. They set a “buy” rating and a $75.00 price target on the stock. Wedbush cut their price objective on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. Finally, Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Buy” and an average price target of $63.80.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $21.77 on Friday. The stock has a market cap of $1.39 billion, a P/E ratio of -8.34 and a beta of 1.28. The firm’s 50-day simple moving average is $24.22 and its 200 day simple moving average is $34.72. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Institutional Investors Weigh In On Vera Therapeutics

A number of large investors have recently made changes to their positions in the company. SG Americas Securities LLC grew its position in Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock worth $857,000 after purchasing an additional 10,916 shares in the last quarter. Barclays PLC raised its position in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock valued at $3,774,000 after buying an additional 41,394 shares during the period. Raymond James Financial Inc. purchased a new stake in Vera Therapeutics in the 4th quarter worth about $2,948,000. Victory Capital Management Inc. grew its stake in Vera Therapeutics by 515.0% during the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company’s stock valued at $9,949,000 after acquiring an additional 197,014 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in shares of Vera Therapeutics by 44.2% in the 4th quarter. Teacher Retirement System of Texas now owns 12,860 shares of the company’s stock valued at $544,000 after purchasing an additional 3,942 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.